Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ROBYN DAWN HARTVICKSON

Allopathic & Osteopathic Physicians Family Medicine

NPI
1679532659
CMS profile
303021
Location
NEWTON, KS

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$259.38

18 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $259.38 18

By paying entity

PY2020 · entire year · sorted by reported total

Page 1 of 1; records 1–18 of 18 matching records. This page contains 18 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ROBYN DAWN HARTVICKSON

NPI 1679532659 · CMS profile ID 303021

Allopathic & Osteopathic Physicians / Family Medicine

NEWTON, KS

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–18 of 18 matching records. This page contains 18 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1679532659?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ROBYN DAWN HARTVICKSON, NPI 1679532659, CMS profile ID 303021. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–18 of 18 matching records. This page contains 18 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1679532659?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). ROBYN DAWN HARTVICKSON, NPI 1679532659, CMS profile ID 303021. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–18 of 18 matching records. This page contains 18 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1679532659?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
ROBYN DAWN HARTVICKSON, NPI 1679532659, CMS profile ID 303021, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–18 of 18 matching records. This page contains 18 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1679532659?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

18 matching records · $259.38 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 18 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–18 of 18.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Biohaven Pharmaceuticals, Inc. $23.6112/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 748977129 CMS
Allergan, Inc. $20.8611/05/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723693163 CMS
Amgen Inc. $14.4810/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741289593 CMS
Merck Sharp & Dohme Corporation $13.1009/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747763915 CMS
Eisai Inc. $14.2909/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751221001 CMS
Eisai Inc. $23.8606/29/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 751213831 CMS
AstraZeneca Pharmaceuticals LP $11.9706/26/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735855653 CMS
Allergan, Inc. $18.5906/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 723693161 CMS
Novo Nordisk Inc $11.0606/23/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744764111 CMS
Kowa Pharmaceuticals America, Inc. $16.9105/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 716729595 CMS
Novo Nordisk Inc $12.3305/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 744693691 CMS
Astellas Pharma US Inc $16.4703/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 718331571 CMS
Merck Sharp & Dohme Corporation $8.0602/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747692269 CMS
PFIZER INC. $1.1102/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743695758 CMS
PFIZER INC. $6.0602/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743695905 CMS
Amgen Inc. $20.8801/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 741289595 CMS
Novartis Pharmaceuticals Corporation $13.1701/17/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725791995 CMS
AstraZeneca Pharmaceuticals LP $12.5701/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 735919093 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $349.87 24
PY2020 $259.38 18
PY2021 $867.92 59
PY2022 $1,012.70 73
PY2023 $2,574.33 71
PY2024 $862.16 54
PY2025 $813.93 47

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $136,207.90 39
PY2024 Principal investigator $344,898.92 54
PY2023 Principal investigator $702,129.77 95
PY2022 Principal investigator $153,146.27 62
PY2021 Principal investigator $143,310.07 45
PY2020 Principal investigator $223,270.91 168
PY2019 Principal investigator $302,825.41 141

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

54 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ModernaTX, Inc. $7,026.75 12/11/2024 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147154893
Principal investigator 1 Organon LLC $20,531.60 12/11/2024 Non-covered Recipient Entity
Alliance for Multispecialty Research, LLC
OG-8175A-023 No dispute reported 06/30/2026 1125523387
Principal investigator 1 ModernaTX, Inc. $1,000.00 12/02/2024 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147154895
Principal investigator 1 ModernaTX, Inc. $1,500.00 12/02/2024 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147154897
Principal investigator 1 ModernaTX, Inc. $67.50 11/27/2024 Non-covered Recipient Entity
ROCHESTER CLINICAL RESEARCH
A Phase 1/2, Randomized, Observer-Blind, Controlled, Dose-Ranging Study of mRNA-1608, an HSV-2 Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1147145110
Principal investigator 1 ModernaTX, Inc. $1,433.70 11/27/2024 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A Phase 1/2, Randomized, Observer-Blind, Controlled, Dose-Ranging Study of mRNA-1608, an HSV-2 Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1147155233
Principal investigator 1 ModernaTX, Inc. $6,345.00 11/20/2024 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147154871
Principal investigator 1 ModernaTX, Inc. $10,914.75 10/18/2024 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147154837
Principal investigator 1 ModernaTX, Inc. $14,991.75 10/18/2024 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147154839
Principal investigator 1 ModernaTX, Inc. $716.85 09/27/2024 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A Phase 1/2, Randomized, Observer-Blind, Controlled, Dose-Ranging Study of mRNA-1608, an HSV-2 Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1147155147
Principal investigator 1 ModernaTX, Inc. $2,922.75 09/18/2024 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A Phase 1/2, Randomized, Observer-Blind, Controlled, Dose-Ranging Study of mRNA-1608, an HSV-2 Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1147155143
Principal investigator 1 ModernaTX, Inc. $7,250.00 09/04/2024 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147154817
Principal investigator 1 ModernaTX, Inc. $1,799.55 08/28/2024 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A Phase 1/2, Randomized, Observer-Blind, Controlled, Dose-Ranging Study of mRNA-1608, an HSV-2 Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1147155065
Principal investigator 1 ModernaTX, Inc. $15,749.10 08/23/2024 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147154791
Principal investigator 1 ModernaTX, Inc. $300.00 08/22/2024 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A Phase 1/2, Randomized, Observer-Blind, Controlled, Dose-Ranging Study of mRNA-1608, an HSV-2 Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1147155063
Principal investigator 1 ModernaTX, Inc. $1,021.95 08/16/2024 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A Phase 1/2, Randomized, Observer-Blind, Controlled, Dose-Ranging Study of mRNA-1608, an HSV-2 Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1147155061
Principal investigator 1 Novavax Inc $4,250.00 08/02/2024 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A Phase 3, Randomized, Double-Blinded Study to Evaluate the Safety and Immunogenicity of Omicron Subvariant and Bivalent SARS-CoV-2 rS Vaccines in Adolescents Previously Vaccinated With mRNA COVID-19 Vaccines No dispute reported 06/30/2026 1123374463
Principal investigator 1 ModernaTX, Inc. $716.85 07/29/2024 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A Phase 1/2, Randomized, Observer-Blind, Controlled, Dose-Ranging Study of mRNA-1608, an HSV-2 Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1147154933
Principal investigator 1 Novavax Inc $333.00 07/25/2024 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A Phase 3, Randomized, Double-Blinded Study to Evaluate the Safety and Immunogenicity of Omicron Subvariant and Bivalent SARS-CoV-2 rS Vaccines in Adolescents Previously Vaccinated With mRNA COVID-19 Vaccines No dispute reported 06/30/2026 1123376069
Principal investigator 1 ModernaTX, Inc. $1,040.00 07/19/2024 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147154751
Principal investigator 1 ModernaTX, Inc. $12,200.35 07/19/2024 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147154755
Principal investigator 1 ModernaTX, Inc. $1,300.00 07/18/2024 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A Phase 1/2, Randomized, Observer-Blind, Controlled, Dose-Ranging Study of mRNA-1608, an HSV-2 Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1147154929
Principal investigator 1 ModernaTX, Inc. $716.85 06/27/2024 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A Phase 1/2, Randomized, Observer-Blind, Controlled, Dose-Ranging Study of mRNA-1608, an HSV-2 Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1147155041
Principal investigator 1 Novavax Inc $296.00 06/26/2024 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A Phase 3, Randomized, Double-Blinded Study to Evaluate the Safety and Immunogenicity of Omicron Subvariant and Bivalent SARS-CoV-2 rS Vaccines in Adolescents Previously Vaccinated With mRNA COVID-19 Vaccines No dispute reported 06/30/2026 1123376625
Principal investigator 1 ModernaTX, Inc. $1,340.00 06/24/2024 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A Phase 1/2, Randomized, Observer-Blind, Controlled, Dose-Ranging Study of mRNA-1608, an HSV-2 Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1147155039
Principal investigator 1 ModernaTX, Inc. $12,164.10 06/20/2024 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147154739
Principal investigator 1 ModernaTX, Inc. $640.00 06/19/2024 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A Phase 1/2, Randomized, Observer-Blind, Controlled, Dose-Ranging Study of mRNA-1608, an HSV-2 Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1147155037
Principal investigator 1 ModernaTX, Inc. $11,463.40 05/29/2024 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147154705
Principal investigator 1 ModernaTX, Inc. $3,870.45 05/27/2024 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A Phase 1/2, Randomized, Observer-Blind, Controlled, Dose-Ranging Study of mRNA-1608, an HSV-2 Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1147155005
Principal investigator 1 Novavax Inc $288.00 05/23/2024 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A Phase 3, Randomized, Double-Blinded Study to Evaluate the Safety and Immunogenicity of Omicron Subvariant and Bivalent SARS-CoV-2 rS Vaccines in Adolescents Previously Vaccinated With mRNA COVID-19 Vaccines No dispute reported 06/30/2026 1123378273
Principal investigator 1 ModernaTX, Inc. $3,003.00 05/15/2024 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147154703
Principal investigator 1 ModernaTX, Inc. $720.00 05/01/2024 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147154701
Principal investigator 1 ModernaTX, Inc. $11,913.20 04/24/2024 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147154685
Principal investigator 1 ModernaTX, Inc. $780.00 04/19/2024 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A Phase 1/2, Randomized, Observer-Blind, Controlled, Dose-Ranging Study of mRNA-1608, an HSV-2 Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1147154993
Principal investigator 1 Novavax Inc $14,496.90 04/18/2024 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A Phase 3, Randomized, Double-Blinded Study to Evaluate the Safety and Immunogenicity of Omicron Subvariant and Bivalent SARS-CoV-2 rS Vaccines in Adolescents Previously Vaccinated With mRNA COVID-19 Vaccines No dispute reported 06/30/2026 1123377719
Principal investigator 1 ModernaTX, Inc. $1,283.85 03/28/2024 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A Phase 1/2, Randomized, Observer-Blind, Controlled, Dose-Ranging Study of mRNA-1608, an HSV-2 Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1147154991
Principal investigator 1 ModernaTX, Inc. $12,740.00 03/22/2024 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147154655
Principal investigator 1 ModernaTX, Inc. $6,200.55 03/21/2024 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A Phase 1/2, Randomized, Observer-Blind, Controlled, Dose-Ranging Study of mRNA-1608, an HSV-2 Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1147154989
Principal investigator 1 Novavax Inc $27,675.90 03/21/2024 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A Phase 3, Randomized, Double-Blinded Study to Evaluate the Safety and Immunogenicity of Omicron Subvariant and Bivalent SARS-CoV-2 rS Vaccines in Adolescents Previously Vaccinated With mRNA COVID-19 Vaccines No dispute reported 06/30/2026 1123376627
Principal investigator 1 ModernaTX, Inc. $1,340.00 02/28/2024 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147154469
Principal investigator 1 ModernaTX, Inc. $13,472.55 02/28/2024 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147154473
Principal investigator 1 ModernaTX, Inc. $20,868.25 02/28/2024 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147154481
Principal investigator 1 ModernaTX, Inc. $22,375.45 02/28/2024 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A Phase 1/2, Randomized, Observer-Blind, Controlled, Dose-Ranging Study of mRNA-1608, an HSV-2 Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1147154959
Principal investigator 1 Novavax Inc $20,660.62 02/15/2024 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A Phase 3, Randomized, Double-Blinded Study to Evaluate the Safety and Immunogenicity of Omicron Subvariant and Bivalent SARS-CoV-2 rS Vaccines in Adolescents Previously Vaccinated With mRNA COVID-19 Vaccines No dispute reported 06/30/2026 1123374963
Principal investigator 1 PFIZER INC. $1,150.00 02/14/2024 Non-covered Recipient Entity
Alliance for MultiSpeciality Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 1131098695
Principal investigator 1 PFIZER INC. $3,750.00 02/10/2024 Non-covered Recipient Entity
Alliance for MultiSpeciality Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 1131098701
Principal investigator 1 ModernaTX, Inc. $3,000.00 02/08/2024 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A Phase 1/2, Randomized, Observer-Blind, Controlled, Dose-Ranging Study of mRNA-1608, an HSV-2 Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1147154957
Principal investigator 1 Novavax Inc $740.00 02/08/2024 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A Phase 3, Randomized, Double-Blinded Study to Evaluate the Safety and Immunogenicity of Omicron Subvariant and Bivalent SARS-CoV-2 rS Vaccines in Adolescents Previously Vaccinated With mRNA COVID-19 Vaccines No dispute reported 06/30/2026 1123377717
Principal investigator 1 ModernaTX, Inc. $1,120.00 02/07/2024 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1147154467
Principal investigator 1 SANOFI PASTEUR INC. $624.80 01/24/2024 Non-covered Recipient Entity
Alliance For Multispecialty Research LLC
Safety, Immunogenicity, Infectivity, and Dose-Finding Study of an Investigational Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in Infants and Toddlers No dispute reported 06/30/2026 1128700268
Principal investigator 1 PFIZER INC. $300.00 01/20/2024 Non-covered Recipient Entity
Alliance for MultiSpeciality Research LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 1131107208
Principal investigator 1 Novavax Inc $18,883.60 01/18/2024 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A Phase 3, Randomized, Double-Blinded Study to Evaluate the Safety and Immunogenicity of Omicron Subvariant and Bivalent SARS-CoV-2 rS Vaccines in Adolescents Previously Vaccinated With mRNA COVID-19 Vaccines No dispute reported 06/30/2026 1123376623
Principal investigator 1 GlaxoSmithKline, LLC. $220.00 01/12/2024 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
PHASE IIIB, OBSERVER-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENT No dispute reported 06/30/2026 1127543043
Principal investigator 1 ModernaTX, Inc. $13,390.00 01/08/2024 Non-covered Recipient Entity
ALLIANCE FOR MULTISPECIALTY RESEARCH LLC
A Phase 1/2, Randomized, Observer-Blind, Controlled, Dose-Ranging Study of mRNA-1608, an HSV-2 Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1147154919